INTRODUCTION: The main goal of this study was to describe the Czech population of patients with MG in terms of demographics, disease characteristics, management approaches, and treatment trends. METHODS: We selected all patients, both incident and prevalent, who were enrolled in the Czech MyReg registry between August 24, 2015 and November 19, 2021. For the descriptive analysis, all patients enrolled in the registry, regardless of their date of diagnosis or date of enrolment, were included. We analyzed the following disease-related endpoints: myasthenia gravis composite (MGC) score, forced vital capacity (FVC), and Myasthenia Gravis Foundation of America (MGFA) clinical classification. RESULTS: The incidence showed a consistent increasing trend from 0.62 to 3.13. The mean MGC score was 5.0 (median 4.0, 95% CI 4.7, 5.3) representing mild form of MG. The difference in FVC from the predicted value in patients during and without myasthenic crisis was 58.93% (95% CI 37.27, 80.59) and 75.93% (95% CI 74.87, 77.00), respectively. We identified 70 patients (5.0%) with refractory MG, of whom 58.6% were female. The MGFA classifications in those with refractory vs. non-refractory disease was as follows: IIa 21.8% vs 23.2%, IIb 45.3% vs 33.6%, and IIIb 14.1% vs 4.6%, respectively. CONCLUSION: Our analysis shows that the incidence of MG is increasing in the Czech Republic and that patients with refractory disease, of whom up to 58% are female, have a higher burden of disease than non-refractory patients.

CEEOR S R O Prague Czech Republic

Department of Biomedical Technology Czech Technical University Prague Kladno Czech Republic

Department of Neurology and Center for Clinical Neuroscience 1st Faculty of Medicine and General University Hospital Charles University Prague Prague Czech Republic

Department of Neurology Neuromuscular Centre University Hospital Brno Brno Czech Republic

Department of Neurology University Hospital Ostrava Czech Republic

Department of Rehabilitation University Hospital Brno Brno Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

UCB Pharma Prague Czech Republic

UCB Pharma Warsaw Poland

Zobrazit více v PubMed

Verschuuren JJGM, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, Gomez AM, de Baets MH, Losen M. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013. 10.1016/j.autrev.2013.03.001. PubMed

Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015. 10.1016/S1474-4422(15)00145-3. PubMed

Heldal A, Owe J, Gilhus N, Romi F. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73:150–1. 10.1212/WNL.0b013e3181ad53c2. PubMed

Deenen J, Horlings C, Verschuuren J, Verbeek A, van Engelen B. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2:73–85. PubMed

Westerberg E, Punga AR. Epidemiology of myasthenia gravis in Sweden 2006–2016. Brain Behav. 2020. 10.1002/brb3.1819. PubMed PMC

Lee HS, Lee HS, Shin HY, Choi YC, Kim SM. The epidemiology of myasthenia gravis in Korea. Yonsei Med J. 2016. 10.3349/ymj.2016.57.2.419. PubMed PMC

Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016. 10.1016/j.nmd.2015.10.009. PubMed

Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol. 2004. 10.1055/s-2004-829593. PubMed

Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021. 10.25122/jml-2020-0145. PubMed PMC

Martinka I, Fulova M, Spalekova M, Spalek P. Epidemiology of myasthenia gravis in Slovakia in the years 1977–2015. Neuroepidemiology. 2018. 10.1159/000487886. PubMed

Pallaver F, Riviera AP, Piffer S, et al. Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology. 2011. 10.1159/000328863. PubMed

Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019. 10.1177/1756286419832242. PubMed PMC

Tran C, Biswas A, Mendoza M, Katzberg H, Bril V, Barnett C. Performance of different criteria for refractory myasthenia gravis. Eur J Neurol. 2021. 10.1111/ene.14675. PubMed

Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve. 2019. 10.1002/mus.26694. PubMed PMC

Vélez-Santamaría V, Nedkova V, Díez L, Homedes C, Alberti MA, Casasnovas C. Eculizumab as a promising treatment in thymoma-associated myasthenia gravis. Ther Adv Neurol Disord. 2020. 10.1177/1756286420932035. PubMed PMC

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019. 10.1002/mus.26447. PubMed PMC

Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, et al. International Consensus Guidance for management of myasthenia gravis: 2020 update. Neurology. 2021. 10.1212/WNL.0000000000011124. PubMed PMC

Piťha J, Bednařík J, Zapletalová O, et al. Guideline for the diagnosis and therapy of myasthenia gravis. Czech Slovak Neurol Neurosurg. 2012;75:242–52.

Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Health West Pac. 2020. 10.1016/j.lanwpc.2020.100063. PubMed PMC

Horáková M, Martinka I, Voháňka S, Špalek P, Bednařík J. A comparative study of myasthenic patients in the Czech and Slovak Republics. Ces Slov Neurol Neurochir. 2019. 10.14735/AMCSNN2019171.

Mevius A, Jöres L, Biskup J, et al. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord. 2023. 10.1016/j.nmd.2023.02.002. PubMed

Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018. 10.1177/1756285617749134. PubMed PMC

Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000. 10.1212/wnl.55.1.16. PubMed

Burns TM, Conaway M, Sanders DB. The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010. 10.1212/WNL.0b013e3181dc1b1e. PubMed PMC

Burns TM, Grouse CK, Conaway MR, et al. Hobson-Webb LD, Tucker-Lipscomb B, et al. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010. 10.1002/mus.21609. PubMed

Burns TM, Conaway MR, Cutter GR, et al. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008. 10.1002/mus.21053. PubMed

Alkhawajah NM, Oger J. Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve. 2013. 10.1002/mus.23964. PubMed

McCombe P, Greer J, Mackay I. Sexual dimorphism in autoimmune disease. Curr Mol Med. 2009;9:1058–79. PubMed

Shepherd R, Cheung AS, Pang K, Saffery R, Novakovic B. Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics. Front Immunol. 2021. 10.3389/fimmu.2020.604000. PubMed PMC

Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015. 10.1016/j.jocn.2015.01.022. PubMed

Twork S, Wiesmeth S, Klewer J, Pöhlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010. 10.1186/1477-7525-8-129. PubMed PMC

Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014. 10.1097/CND.0000000000000034. PubMed

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016. 10.1056/nejmoa1602489. PubMed PMC

Kim AG, Upah SA, Brandsema JF, Yum SW, Blinman TA. Thoracoscopic thymectomy for juvenile myasthenia gravis. Pediatr Surg Int. 2019. 10.1007/s00383-019-04441-0. PubMed PMC

Mcsweyn NF, Schwarz H. Thymectomy in myasthenia gravis. Can Med Assoc J. 1954. 10.5152/eurasianjmed.2017.17009. PubMed PMC

Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data